Tiffani Johnson, MD, MSC, FAAP, enthralled a packed room at the American Academy of Pediatrics 2019 National Conference & Exhibition Friday afternoon when she led session attendees to admit that they ...

FDA approves guselkumab for children with plaque psoriasis and psoriatic arthritis ...

IDWeek 2025 heads to Atlanta October 19–22 with cutting-edge sessions on AMR, AI, vaccines, HIV, pediatrics, and global health challenges. The infectious diseases community will gather in Atlanta from ...

FDA approves roflumilast cream 0.05% for atopic dermatitis for children aged 2 to 5 years ...

Getting children who have asthma into the water can have remarkable effects on health, the authors' experiences demonstrate. Place a properly structured swimming program on your list of ...

Affecting between 15% to 20% of children and adolescents, anxiety disorders are the most prevalent psychiatric condition in pediatrics. The impact can be significant with difficulties in social and ...

At a minimum, the pediatrician should be familiar with genetic disease on the newborn screen and other genetic diseases they may see in their office. It’s also important to recognize the child with ...

A 15-year-old adolescent Caucasian male with no significant past medical history presented to the clinic with gradually worsening left ankle pain over the past 2 weeks, ever since he started his ...

A 5-month-old Hispanic male presented to the emergency department (ED) at a children’s hospital in the Northeast United States directly from his daycare after caretakers witnessed 2 shaking, ...

Dr Taylor is associate professor of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania, and attending physician, St. Christopher’s Hospital for Children, Philadelphia.

A 14-year-old girl came to the office with severe hip pain, which occurred after she attempted a cheerleading maneuver on a trampoline. She reported that she was bouncing as high as she could and ...

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years. A newly approved nonsteroidal topical ...